Alnylam Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Alnylam Pharmaceuticals' es Yvonne Greenstreet , nombrado en Jan 2022, tiene una permanencia de 2.25 años. compensación anual total es $8.90M, compuesta por 11% salario y 89% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.038% de las acciones de la empresa, por valor de $7.09M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 8.4 años, respectivamente.
Información clave
Yvonne Greenstreet
Chief Executive Officer (CEO)
US$8.9m
Compensación total
| Porcentaje del salario del CEO | 11.0% |
| Permanencia del CEO | 2.3yrs |
| Participación del CEO | 0.04% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 8.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking
Mar 19
Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think
Feb 18Alnylam's Huge Opportunity
Jan 12Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues
Dec 18Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares
Jun 23Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
Oct 25Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo
Oct 07Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market
Sep 26Alnylam RNAi therapy for rare protein disorder gets EU approval
Sep 20Alnylam to offer $900M convertible senior notes
Sep 12Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy
Aug 29Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity
Aug 18APOLLO Hits A Bullseye, And Alnylam Logs Another Major Clinical Win
Aug 04Alnylam to target abdominal obesity after research data on gene mutation
Jul 27Alnylam Pharmaceuticals Heading Toward A Key Trial Read-Out
Jul 19Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?
Jun 21Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$9m | US$976k | -US$440m |
| Sep 30 2023 | n/a | n/a | -US$510m |
| Jun 30 2023 | n/a | n/a | -US$1b |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$5m | US$850k | -US$1b |
| Sep 30 2022 | n/a | n/a | -US$1b |
| Jun 30 2022 | n/a | n/a | -US$981m |
| Mar 31 2022 | n/a | n/a | -US$893m |
| Dec 31 2021 | US$9m | US$619k | -US$853m |
| Sep 30 2021 | n/a | n/a | -US$838m |
| Jun 30 2021 | n/a | n/a | -US$887m |
| Mar 31 2021 | n/a | n/a | -US$876m |
| Dec 31 2020 | US$3m | US$622k | -US$858m |
| Sep 30 2020 | n/a | n/a | -US$891m |
| Jun 30 2020 | n/a | n/a | -US$846m |
| Mar 31 2020 | n/a | n/a | -US$886m |
| Dec 31 2019 | US$3m | US$571k | -US$886m |
| Sep 30 2019 | n/a | n/a | -US$821m |
| Jun 30 2019 | n/a | n/a | -US$858m |
| Mar 31 2019 | n/a | n/a | -US$802m |
| Dec 31 2018 | US$3m | US$540k | -US$761m |
| Sep 30 2018 | n/a | n/a | -US$692m |
| Jun 30 2018 | n/a | n/a | -US$570m |
| Mar 31 2018 | n/a | n/a | -US$525m |
| Dec 31 2017 | US$985k | US$504k | -US$491m |
Compensación vs. Mercado: La compensación total de Yvonne($USD8.90M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD13.52M).
Compensación vs. Ingresos: La compensación de Yvonne ha aumentado mientras la empresa no es rentable.
CEO
Yvonne Greenstreet (60 yo)
2.3yrs
Permanencia
US$8,895,670
Compensación
Dr. Yvonne L. Greenstreet, MBChB, MBA, is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. Dr. Greenstreet joined the Alnylam Pharmaceuticals, Inc. on September 19, 2016. Sh...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$8.90m | 0.038% $ 7.1m | |
| CFO & Executive VP | 4.7yrs | US$3.22m | 0.015% $ 2.9m | |
| Chief Innovation Officer & Member of the Scientific Advisory Board | less than a year | US$3.32m | 0.018% $ 3.4m | |
| Chief Medical Officer and Executive VP of Development & Medical Affairs | 9.5yrs | US$3.23m | 0.0074% $ 1.4m | |
| Executive VP & Chief Commercial Officer | 3.3yrs | US$2.87m | 0.0041% $ 764.7k | |
| Chief Technical Operations & Quality Officer | 1.3yrs | sin datos | sin datos | |
| Senior VP | 4.9yrs | sin datos | 0.011% $ 2.0m | |
| Senior VP of Investor Relations & Corporate Communications | no data | sin datos | sin datos | |
| Chief Ethics & Compliance Officer | 1.6yrs | sin datos | sin datos | |
| Chief Corporate Development & Strategy Officer | 1.6yrs | sin datos | sin datos | |
| Chief Human Resource Officer | 4.9yrs | sin datos | sin datos | |
| Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board | no data | sin datos | sin datos |
2.8yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ALNY se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 2.5yrs | US$8.90m | 0.038% $ 7.1m | |
| Chief Innovation Officer & Member of the Scientific Advisory Board | no data | US$3.32m | 0.018% $ 3.4m | |
| Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board | 8.5yrs | sin datos | sin datos | |
| Independent Director | 1.1yrs | US$658.72k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | US$516.04k | sin datos | |
| Independent Director | 8.3yrs | US$477.21k | 0.022% $ 4.1m | |
| Co-Founder | 21.8yrs | US$502.21k | 0.21% $ 39.0m | |
| Independent Chair of the Board & Lead Independent Director | 9.8yrs | US$531.36k | 0.00011% $ 20.3k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board & Independent Director | 12yrs | US$477.21k | 0.0029% $ 532.0k | |
| Independent Director | 5.8yrs | US$489.15k | 0% $ 0 |
8.4yrs
Permanencia media
68.5yo
Promedio de edad
Junta con experiencia: La junta directiva de ALNY se considera experimentada (8.4 años de antigüedad promedio).